Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in alpha-1 antitrypsin deficiency (AATD), Beam Therapeutics is seeking to ...

Macy is a writer on the AI Team. She covers how AI is changing daily life and how to make the most of it. This includes writing about consumer AI products and their real-world impact, from ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

Patients Required a Median of One Cell Collection Cycle and Experienced Rapid Neutrophil and Platelet Engraftment ...